Product category:
Antibodies
News Release from: Oxford BioMedica
Edited by the Laboratorytalk Editorial
Team on 20 December 2006
Expanded licencing agreement for
Lentivector
Oxford BioMedica has expanded an existing licence agreement for its LentiVector technology with a major multinational pharmaceutical company
The amendment broadens the agreement from an annual license for use of Oxford BioMedica's gene delivery technology for research activities in the USA to a world-wide perpetual license Under the terms of the amended agreement, Oxford BioMedica will receive a one-time undisclosed payment from the licensee
This article was originally published on Laboratorytalk on 25 Jun 2003 at 8.00am (UK)
Related stories
Manufacturing process for Parkinson's drug
First discussion of the novel production approach used for ProSavin, a LentiVector-based product, to be made at Bio 2003 this week in Washington DC.
Oxford BioMedica's lentivirus-based gene delivery technology, known as LentiVector, is said to be one of the most powerful technologies for the delivery of genes to a wide range of cell and tissue types.
The LentiVector technology has applications both in therapeutic products and as a drug discovery tool for target validation and the creation of targeted disease models.
Oxford BioMedica has a comprehensive portfolio of US and European patents that cover the technology.
The company has an active licensing programme providing access to its LentiVector technology on a non-exclusive basis primarily.
Licensees include Biogen Idec, Merck, and Pfizer.
• Oxford BioMedica: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
